trans-Sabinol is a bicyclic monoterpene alcohol most strongly associated with sabinol- and sabinyl-ester-rich Achillea and wormwood chemotypes. The live evidence base is strongest for identity, plant occurrence, and a limited but real preclinical toxicology and neuroactivity literature rather than for broad standalone wellness use. For AromaForge, the safest positioning is as a rare chemotype-defining alcohol with moderate preclinical acetylcholinesterase and antinociceptive signals, plus a meaningful safety halo inherited from sabinol-derivative-rich poisonous or abortifacient plant contexts.
Chemical identity and composition
NIST lists trans-Sabinol as C10H16O with CAS 29606-76-6 and also names it (E)-sabinol. In public occurrence literature, it commonly appears next to trans-sabinyl acetate and related sabinol esters in Achillea falcata, Achillea fragrantissima, Achillea tenorii, and low-thujone Artemisia absinthium profiles, which makes it more useful as a chemotype marker than as a broadly studied isolated fragrance molecule.
Aroma and practical use
- Use the recorded green, herbal, camphoraceous, fresh, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A Food and Chemical Toxicology paper on Achillea falcata reported that trans-sabinol and multiple trans-sabinol esters were identified in both aerial and underground parts of the plant after spectral analysis, synthesis, and theoretical study.
This is the strongest directly readable source in this pass tying the constituent to a real plant chemotype rather than to a database-only entry.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
The same 2015 study reported moderate acute toxicity in the Artemia salina model, moderate acetylcholinesterase inhibition, and peripheral and central antinociceptive signals for trans-sabinol and its esters.
These are isolated-compound or enriched-compound preclinical findings, not human evidence.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2020 Achillea fragrantissima paper reported trans-sabinol as a major component in both leaf oil and stem oil, at 14.9 +/- 0.13% and 19.2 +/- 0.01%, respectively.
This supports the constituent's role as a genuine major marker in some Achillea oils rather than a trace analyte.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
The 2026 low-thujone wormwood paper reported trans-sabinol at 5.9 +/- 2.1% alongside trans-sabinyl acetate-rich oils.
This extends the constituent's archive relevance into wormwood profiles, especially sabinyl-acetate-dominant low-thujone material.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedThe clearest direct safety signal is preclinical: the Achillea falcata paper reported moderate acute toxicity for trans-sabinol and related esters in the Artemia salina model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
The Achillea fragrantissima full text explicitly notes that poisonous Juniperus sabina literature attributes kidney congestion, hematuria, menorrhagia, and abortion concern to trans-sabinol and related sabinol derivatives, so pregnancy-focused caution is reasonable even though the source is discussing plant-level toxicity rather than isolated modern dosing studies.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
A constituent-specific IFRA-style dermal limit or modern human toxicology package for isolated trans-sabinol was not verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
moderate acetylcholinesterase inhibition in isolated-compound screening
The best directly readable isolated-compound paper found in this pass reports that trans-sabinol and related esters reduced acetylcholinesterase activity by up to about 40% at 20 microg/mL in enzyme testing.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- I did not verify a constituent-specific public CAS or safety entry from The Good Scents Company for the stereospecific trans isomer; the Good Scents page found in this pass appears to cover generic sabinol.
- No human clinical literature specific to isolated trans-sabinol was located in the reviewed sources.
- A direct modern dermal sensitization, irritation, or phototoxicity dataset for isolated trans-sabinol was not verified in this pass.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.